Log in
Biology
2
answers
0
watching
6
views
12 Dec 2019

Consider a material for a vascular graft application with proteins absorbed to its surface and a second material with proteins covalently attached to its surface. For which material would you expect the protein layer to be more stable under flow conditions similar to those found in a blood vessel? Why?

Watch
2
answers
0
watching
6
views

For unlimited access to Homework Help, a Homework+ subscription is required.

Unlock all answers

Get 1 free homework help answer.
Get unlimited access
Already have an account? Log in
Share
Trinidad Tremblay
Trinidad TremblayLv2
13 Dec 2019
Get unlimited access
Already have an account? Log in
Share

Related textbook solutions

Molecular Cell Biology
8 Edition,
Lodish
ISBN: 9781464183393
Biology: Science for Life with Physiology
6 Edition,
Belk
ISBN: 9780134555430
Biology
2nd Edition, 2013
Openstax
ISBN: 9781947172517
Concepts of Biology
OER Edition,
Openstax
ISBN: 9781938168116
Essentials of Biology
5 Edition,
Mader
ISBN: 9781259660269

Related questions

You are given responsibility for purifying a protein, the isozyme phosphofructokinase-1 C (PFK-1 C, an enzyme of glycolysis). There are three isozymes (multiple forms of an enzyme) of PFK-1 and they are designated A, B, and C. The A isozyme (MW = 84,000 dal) is found in the muscle and the brain; the B isozyme (MW = 80,000 dal) is found in the liver and the brain; and the C isozyme (MW = 86,000 dal) is found in the brain. Following a protocol for the purification, you proceed through the steps below. Your advisor asks you questions about your techniques. Provide the answers below

You proceed with the purification using the soluble protein fraction that resulted from the centrifugation steps above. You run the soluble proteins over an ATP-Sepharose chromatographic column. This is an affinity column in which ATP is covalently linked to a polysaccharide bead (FYI – ATP is a substrate of the PFK enzyme). The sample is loaded on top of the column, washed with a low-salt buffer, followed by a wash with a high salt buffer. The proteins are then eluted from the column.

After the soluble proteins are added to the column, do you expect PFK-1C to flow directly through the column or will its migration be slowed? Explain your reasoning.

What is the purpose of washing with a low salt and then a high salt buffer? Why are both washes needed?

1) In the major biosynthetic pathway, what is the order in which mRNA moves through the various organelles?

2) Compare and contrast the structure and function of the smooth endoplasmic reticulum and the rough endoplasmic reticulum?

3) Is SAR1 COPI or COPII? What type of protein is this? What causes SAR1 to active and what protein is necessary for this to occur?
4) Dynamin binds where clathrin meets the plasma membrane. As dynamin binds, it forms a ring that is then pinched so that the vesicle can be released from the plasma membrane. What allows for this to occur?

5) What are three different mechanisms of protein translocation? Briefly describe the state of the proteins when translocated in each of these ways.

6) What is the KDEL sequence stand for and how does it function within the cell? What type of transport is it associated with?

7) In what cellular compartment would a glycoprotein be expected to have its greatest mannose content? Its greatest N-acetylglucosamine content? Its greatest sialic acid content?

8) Would you expect the properties of the cisternal side of Golgi membranes to be more similar to the extracellular or cytosolic side of the plasma membrane? Why?

9) ________ are the site of cellular digestion, in which digestion occurs with the help of 50 __________. _____ digest proteins and ____ digest lipids.

10) Name two proteins you would expect to find as integral components of the RER membrane that would be absent from the SER? Name two proteins of the SER that would not be present in the RER?

1.In 1971, Dr. Judah Folkman published the “angiogenic hypothesis” suggesting that a tumor cannot grow beyond 1–2 millimeters without the development of new blood vessels (angiogenesis) that provide access to oxygen and nutrients. During the 1990s, it was discovered that vascular endothelial growth factor (VEGF) stimulates migration and proliferation of the cells that form blood vessels, leading to the formation of new blood vessels. VEGF binds to receptor tyrosine kinases (RTKs) on the cell surface and causes the RTKs to dimerize and become active, thereby initiating an intracellular signaling cascade that stimulates cell division and inhibits apoptosis. Many cancer cells secrete high levels of VEGF and increased VEGF expression in a tumor is correlated with a poor medical outcome for the patient. You work for a biotechnology company that seeks to create anti-cancer drugs that prevent growth of tumors and/or cause tumors to shrink, while leaving normal cells relatively untouched. Your company has purchased the rights to therapeutic uses of VEGF derived proteins as anti-tumor drugs. You have found that the VEGF protein has 2 domains, one involved in receptor binding, the other is required for dimerization of VEGF. You propose to make mutant versions of the protein that will act as antagonists of the receptor to be given to patients as an IV treatment as a way to inhibit the endogenous VEGF secreted by the tumor.

a.Which of the 2 domains should you mutate (receptor binding or dimerization)?

b. How do you expect the introduction of the mutant protein into the bloodstream of patients to block tumor progression (in other words, why did you change the domain in part a)?

Weekly leaderboard

Home
Homework Help 3,900,000
Biology 460,000
Start filling in the gaps now
Log in